Growth in IT-related products
First written in FY2020-Q2. 3 of 6 entries say "Restated". Latest entry: FY2021.
No other company in this theme has enough history to compare yet.
- FY2021DroppedAnnual reportIn the full-year discussion of the biological testing equipment segment, IT-related products are not identified as an independent performance factor, while an increase in large-scale business opportunities is cited as the main factor.
- FY2021-Q3RestatedAnnual report
「Although sales of electrocardiograph-related products and IT-related products declined, large-scale business negotiations increased, resulting in consolidated sales of ¥26,738 million, up 3.9% year on year, and operating profit of ¥1,878 million, up 17.0%.」
The decline in sales of IT-related products is again reported, following the previous quarter, reaffirming the downward trend for these products. - FY2021-Q2RestatedAnnual report
「Sales of electrocardiograph-related products and IT-related products declined, resulting in consolidated sales of ¥15,728 million, down 17.8% year on year, and operating profit of ¥1,041 million, down 21.1%.」
The decline in sales of IT-related products continues to be cited as a performance factor for the biomedical equipment segment, following the previous quarter. - FY2021-Q1IT-related product growth changed to a declineAnnual report
「Sales of electrocardiograph-related products and IT-related products declined, resulting in consolidated sales of ¥6,259 million, down 9.2% year on year, and operating profit of ¥255 million, down 30.1%.」
IT-related products, which had been cited as a driver of revenue growth in the biomedical equipment segment in the same period of the previous fiscal year, were cited as a factor behind lower sales in the first quarter of the current fiscal year. - FY2020-Q3RestatedAnnual report
「Growth in large-scale business negotiations and IT-related products drove consolidated sales to ¥25,730 million, up 6.0% year on year, and operating profit to ¥1,605 million, up 2.7%.」
Growth in IT-related products continues to be cited as a factor behind higher sales and earnings in the biomedical equipment segment. - FY2020-Q2First statedAnnual report
「Growth in large-scale business negotiations and IT-related products drove consolidated sales to ¥19,127 million, up 22.0% year on year, and operating profit to ¥1,319 million, up 24.5%.」
Records for the first time, as an independent theme, growth in IT-related products as a factor behind higher sales and earnings in the biomedical equipment segment.